SCHEMBL2995024

SCHEMBL2995024

CCCN(CCC)[N]CC

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.35
CA2 P00918 3/20 0.35
CA9 Q16790 3/20 0.35
CA1 P00915 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6964215 0.89 CA12 (0.34) CA12CA2CA9CA1
SCHEMBL6974455 0.88
SCHEMBL6974462 0.81 CA12 (0.37) CA12CA2CA9CA1
SCHEMBL1793940 0.78 CA12 (0.33) CA12CA2CA9CA1
SCHEMBL7472255 0.73 DNM1 (0.32) CA12CA2CA9CA1
SCHEMBL6975472 0.71 CA12 (0.37) CA12CA2CA9CA1
SCHEMBL6962139 0.71
SCHEMBL6973884 0.69 CA12 (0.33) CA12CA2CA9CA1
SCHEMBL6962258 0.69 CA12 (0.33) CA12CA2CA9CA1
SCHEMBL8970581 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0711768-B1 BENZIMIDAZOLE DERIVATIVE MITSUI CHEMICALS INC (JP) 2002-02-13 EP claimed
US-7786115-B2 Amide derivatives ASTRAZENECA AB (SE) 2010-08-31 US disclosed
US-20080146566-A1 Amide Derivatives ASTRAZENECA AB (SE) 2008-06-19 US disclosed
EP-0870765-B1 AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS ZERIA PHARM CO LTD (JP) 2003-11-19 EP disclosed
EP-0711768-B1 BENZIMIDAZOLE DERIVATIVE MITSUI CHEMICALS INC (JP) 2002-02-13 EP disclosed
US-5981557-A HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-11-09 US disclosed
US-5852011-A Benzimidazole derivatives MITSUI CHEMICALS, INC. (JP) 1998-12-22 US disclosed
EP-0870765-A1 AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS ZERIA PHARMACEUTICAL CO., LTD. (JP) 1998-10-14 EP disclosed
EP-0711768-A1 BENZIMIDAZOLE DERIVATIVE MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-05-15 EP disclosed
US-4353826-A ANTITUBERCULAR ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1982-10-12 US disclosed
US-4261891-A BACTERICIDES, ANTITUBERCULAR AGENTS CIBA-GEIGY CORPORATION (US) 1981-04-14 US disclosed
US-4109087-A CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1978-08-22 US disclosed
US-4109091-A CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1978-08-22 US disclosed
US-4072679-A CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1978-02-07 US disclosed
US-4066644-A CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1978-01-03 US disclosed
US-4066643-A CNS DEPRESSANTS, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1978-01-03 US disclosed
US-4033958-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1977-07-05 US disclosed
US-4022782-A ANTI-INFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1977-05-10 US disclosed
US-4020072-A PSYCHOTROPIC E. R. SQUIBB & SONS, INC. (US) 1977-04-26 US disclosed
US-3994893-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146566-A1 Amide Derivatives IL6, IL1B, IL1A CA12 3578/4885CA2 2952/4885CA9 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.